Has Eric Simoes received payments from drug or device companies?

Yes. Drug and device makers reported $530,649 in general payments to Eric Simoes across 277 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Eric Simoes did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Eric Simoes come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Eric Simoes

Pediatric Infectious Diseases · Aurora, CONPI 1902981632

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (47.2%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 10 manufacturers reported payments, led by Pfizer at 44.1% of the total. 2025 is the largest year on record at $180,394, 7.4 times the $24,499 reported in 2019. Among pediatric infectious diseases clinicians in CO with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$530,649in general payments, 2019–2025

Across 277 payments — averaging $1915.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Pfizer$234K
Sanofi Pasteur Inc.$99K
Merck$94K
GSK$61K
Modernatx, Inc.$28K
AstraZeneca$12K
plus $3K from 4 others

$11,677,080in research payments, 2019–2025

Across 316 payments — averaging $36,953 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Pfizer$9.1M
Regeneron$1M
Merck$596K
AstraZeneca$448K
Astrazeneca UK Limited$318K
Sanofi Pasteur Inc.$47K
plus $129K from 4 others

What the payments were for

Consulting fees$250,38147%
Speaking & faculty fees$170,52032%
Travel & lodging$103,47619%
Food & beverage$6,2711%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Pfizer(2 entities)	130	$233,829
Sanofi Pasteur Inc.	60	$98,615
Merck	47	$93,738
GSK	11	$60,862
Modernatx, Inc.	2	$28,438
AstraZeneca	16	$12,169
Shionogi Inc	1	$1,300
Astrazeneca UK Limited	4	$1,176
Sobi, Inc	5	$425
Novavax Inc	1	$97

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$530,649 in reported general payments places this provider in the 95th percentile of 20 pediatric infectious diseases providers in Colorado.

See all pediatric infectious diseases providers in Colorado →

Other pediatric infectious diseases in Aurora

Myron LevinAurora$292K
Edwin AsturiasAurora$42K
Samuel DominguezAurora$21K
Daniel OlsonAurora$18K
Mary GlodeAurora$13K
Ann NyquistAurora$8K
Elizabeth McFarlandAurora$3K
Kevin MessacarAurora$3K
Christina Smith-AndersonAurora$268
Michael BozzellaAurora$125

See the full list for Colorado →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →